Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy

Wollina, Uwe; Füller, Jürgen; Graefe, Tim; Kaatz, Martin; Lopatta, Eric

doi:10.1007/s004320000221

Cited by 46 publications

(39 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 One patient achieved a PR with 20 mg/m 2 PLD per month and then had SD with no further shrinkage of the tumor at 21 months, and was then given radiotherapy with control at the time of the report at 24 months after the radiotherapy. 38 Another report described a patient response to PLD combined with IFN-␣, in whom subsequent PD developed when PLD alone was received. The patient then had a subsequent PR when IFN-␣ was given in combination with PLD.…”

Section: Discussionmentioning

confidence: 99%

Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

Skubitz

Haddad

2005

Cancer

187

105

View full text Add to dashboard Cite

BACKGROUNDPaclitaxel has unique activity in angiosarcomas of the face and scalp, but its activity in angiosarcomas originating at other sites is less well defined. Paclitaxel and pegylated‐liposomal doxorubicin (PLD) are highly effective in Kaposi sarcoma (KS). Because of the efficacy of PLD in soft tissue sarcoma in general, and in KS in particular, coupled with potential similarities in KS and angiosarcoma, and the apparent activity of paclitaxel in angiosarcomas, the authors treated patients with angiosarcoma with either paclitaxel or PLD as initial chemotherapy.METHODSTo better define the efficacy of these agents in angiosarcoma, the authors reviewed their experience with paclitaxel and PLD in patients with angiosarcoma treated between 1994 and 2004.RESULTSThey identified seven patients with angiosarcoma treated with paclitaxel, and six treated with PLD. Only one patient in the series had an angiosarcoma of the scalp. Two patients receiving paclitaxel had received previous therapy with PLD, and four of six patients treated with PLD had previously received paclitaxel. Of the eight patients treated with paclitaxel, five had major responses (three had partial responses [PR] and two had complete disease remission [CR]) and three had progressive disease (PD). Of the 6 patients who received PLD, 3 had a PR for 6, 19, and >20 months, respectively, 2 had stable disease for 7 and 11 months, respectively, and 1 had PD.CONCLUSIONSThe current study demonstrated the activity of PLD (five of six patients experienced clinical benefit) and extended the data on paclitaxel in angiosarcoma, both of the face and scalp, as well as angiosarcoma originating at other sites. Cancer 2005. © 2005 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

Skubitz

Haddad

2005

Cancer

187

105

View full text Add to dashboard Cite

show abstract

“…22 Response rates for ifosfamide or doxorubicin in patients with advanced angiosarcoma are approximately 20%. 3 One study that used a combination of doxorubicin and ifosfamide found a response rate of 32% in patients with advanced sarcomas. 23 Another group reported a response rate of 64% in patients with sarcoma, including angiosarcomas, using a dose-intensive regimen of doxorubicin plus ifosfamide.…”

Section: Discussionmentioning

confidence: 99%

“…For those patients, different chemotherapeutic regimens have been described with limited success but with severe toxic side effects. 2,3 In general, patients with metastasized soft tissue sarcomas have a bad prognosis. For untreated patients, the estimated progression-free survival rate after 6 months is approximately 30 -56%, depending on the histopathologic diagnosis.…”

mentioning

confidence: 99%

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

Vogt

Hafner

Bross

et al. 2003

Cancer

135

View full text Add to dashboard Cite

The processing–property relationship of a model cryogenically mechanically alloyed polymer–polymer system [polycarbonate (PC) and poly(aryl ether ether ketone) (PEEK)] was investigated. PC and PEEK powders were cryogenically mechanically alloyed for 10 h, and the resulting two‐phase powder particles were processed into testable coupons with a miniature ram‐injection molder. The bulk mechanical properties of the coupons made from the mechanically alloyed powders and nonmechanically alloyed powders were investigated as a function of mechanical alloying and injection‐molding parameters. The injection‐molded coupons were mechanically tested in the three‐point‐bending mode. The results demonstrated that no measurable improvement was achieved in the energy to break, strain at failure, or failure strength in the coupons made from the mechanically alloyed materials in comparison with those of the coupons made from the nonmechanically alloyed powders. © 2003 Wiley Periodicals, Inc. J Appl Polym Sci 88: 1196–1202, 2003

show abstract

“…Systemic treatment may be used in a neoadjuvant setting, adjuvant setting, and as concurrent treatment with RT. 8,17,18 Conversely, RT plus chemotherapy was not shown to have any prognostic value in a meta-analysis by Shin et al 19 Further studies should be carried out to elucidate the benefit of combined modality treatment.…”

Section: Discussionmentioning

confidence: 99%

Treatment of cutaneous angiosarcoma of the scalp and face in the Chinese patients: local experience at a regional hospital in Hong Kong

Chow

Kwan

2018

Hong Kong Med J

View full text Add to dashboard Cite

Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy

Abstract: Sequential therapy of bad prognosis angiosarcoma with liposomal doxorubicin followed by radiotherapy showed a marked clinical improvement and prolonged relapse-free survival in this patient.

Cited by 46 publications

References 28 publications

Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

Treatment of cutaneous angiosarcoma of the scalp and face in the Chinese patients: local experience at a regional hospital in Hong Kong

Contact Info

Product

Resources

About